EA201790239A1 - Молекула-носитель для антигенов - Google Patents

Молекула-носитель для антигенов

Info

Publication number
EA201790239A1
EA201790239A1 EA201790239A EA201790239A EA201790239A1 EA 201790239 A1 EA201790239 A1 EA 201790239A1 EA 201790239 A EA201790239 A EA 201790239A EA 201790239 A EA201790239 A EA 201790239A EA 201790239 A1 EA201790239 A1 EA 201790239A1
Authority
EA
Eurasian Patent Office
Prior art keywords
conjugate
antigens
antigen
spb1
mammal
Prior art date
Application number
EA201790239A
Other languages
English (en)
Inventor
Франческо Берти
Роберта Коцци
Гвидо Гранди
Доменико Майоне
Иммакулада Маргарит И Рос
Чира Даньела Ринаудо
Original Assignee
Глаксосмитклайн Байолоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Байолоджикалс С.А. filed Critical Глаксосмитклайн Байолоджикалс С.А.
Publication of EA201790239A1 publication Critical patent/EA201790239A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Abstract

В изобретении предложен конъюгат, содержащий антиген и молекулу-носитель, где указанная молекула-носитель содержит антиген ВР-2а и антиген spb1. BP-2a и spb1 представляют собой антигены Streptococcus agalactiae.Конъюгат может найти применение в способе индуцирования иммунного ответа у млекопитающего, включающем введение данного конъюгата млекопитающему. Также предложены фармацевтические композиции, в частности вакцины, содержащие конъюгат.
EA201790239A 2014-08-05 2015-08-05 Молекула-носитель для антигенов EA201790239A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14179945 2014-08-05
PCT/EP2015/068012 WO2016020413A1 (en) 2014-08-05 2015-08-05 Carrier molecule for antigens

Publications (1)

Publication Number Publication Date
EA201790239A1 true EA201790239A1 (ru) 2017-07-31

Family

ID=51298571

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790239A EA201790239A1 (ru) 2014-08-05 2015-08-05 Молекула-носитель для антигенов

Country Status (16)

Country Link
US (1) US10245310B2 (ru)
EP (1) EP3177324A1 (ru)
JP (1) JP2017523985A (ru)
KR (1) KR20170039709A (ru)
CN (1) CN108064174A (ru)
AR (1) AR101455A1 (ru)
AU (1) AU2015299008B2 (ru)
BE (1) BE1022792B1 (ru)
BR (1) BR112017002183A2 (ru)
CA (1) CA2957118A1 (ru)
EA (1) EA201790239A1 (ru)
IL (1) IL250238A0 (ru)
MX (1) MX2017001638A (ru)
SG (1) SG11201700673RA (ru)
WO (1) WO2016020413A1 (ru)
ZA (1) ZA201700824B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431136B2 (en) * 2005-06-27 2013-04-30 Glaxosmithkline Biologicals S.A. Immunogenic composition
US20210108002A1 (en) 2016-12-06 2021-04-15 Glaxosmithkline Biologicals Sa Purification Process For Capsular Polysaccharide
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CA3066020A1 (en) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Method of treatment
WO2019217665A1 (en) * 2018-05-09 2019-11-14 West Virginia University Iron-acquisition receptor peptide administration for vaccination against pseudomonas aeruginosa
KR20210042904A (ko) * 2018-07-04 2021-04-20 박사이트, 인코포레이티드 면역원성 접합체의 개선
WO2020010000A1 (en) * 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
CN108840914B (zh) * 2018-08-13 2022-07-01 内蒙古民族大学 一种具有免疫原性的多肽、其抗体的制备方法以及用途
EA202192401A1 (ru) * 2019-04-02 2022-03-30 Ваксайт, Инк. Оптимизированный бесклеточный синтез плазмидного антигена инвазии в и родственные композиции и способы применения
CA3161857A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
US20230303637A1 (en) 2020-06-12 2023-09-28 Glaxosmithkline Biologicals Sa Gbs ferritin nanoparticles
WO2021250626A2 (en) * 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Dock tag system
CN112979797B (zh) * 2021-04-28 2022-04-01 中国检验检疫科学研究院 一种抗赤羽病病毒单克隆抗体及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008508320A (ja) * 2004-07-29 2008-03-21 カイロン コーポレイション Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのようなグラム陽性細菌に対する免疫原性組成物
CA2591510A1 (en) * 2004-12-22 2006-06-29 Novartis Vaccines And Diagnostics, Inc. Group b streptococcus
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0605757D0 (en) * 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
WO2009027768A2 (en) * 2006-07-26 2009-03-05 Novartis Ag Immunogenic compositions for gram positive bacteria
GB0802503D0 (en) * 2008-02-11 2008-03-19 Novartis Ag Hybrid polypeptide
US8465751B2 (en) * 2009-01-12 2013-06-18 Novartis Ag Cna—B domain antigens in vaccines against gram positive bacteria
GB201003333D0 (en) * 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201005625D0 (en) * 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
GB201114923D0 (en) * 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
CA2865028A1 (en) * 2012-02-24 2013-08-29 Novartis Ag Pilus proteins and compositions

Also Published As

Publication number Publication date
AU2015299008B2 (en) 2018-08-02
AU2015299008A1 (en) 2017-02-23
US10245310B2 (en) 2019-04-02
MX2017001638A (es) 2017-04-27
AR101455A1 (es) 2016-12-21
BE1022792B1 (fr) 2016-09-06
BE1022792A1 (fr) 2016-09-06
BR112017002183A2 (pt) 2018-01-16
IL250238A0 (en) 2017-03-30
KR20170039709A (ko) 2017-04-11
SG11201700673RA (en) 2017-02-27
CA2957118A1 (en) 2016-02-11
US20170224803A1 (en) 2017-08-10
EP3177324A1 (en) 2017-06-14
JP2017523985A (ja) 2017-08-24
WO2016020413A1 (en) 2016-02-11
ZA201700824B (en) 2019-07-31
CN108064174A (zh) 2018-05-22

Similar Documents

Publication Publication Date Title
EA201790239A1 (ru) Молекула-носитель для антигенов
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
EA201790248A1 (ru) Композиции носитель-антитело и способы их получения и применения
CU20160101A7 (es) Inmunoglobulina con fab en tándem
EA201991715A1 (ru) Композиции, содержащие антитело к pdl1
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
NZ762843A (en) Anti-egfr antibodies and antibody drug conjugates
JO3772B1 (ar) صيغة جسم مضاد لـ cgrp
EA201590388A1 (ru) Способы лечения таупатии
PH12016501976A1 (en) Antibodies, pharmaceutical compositions and uses thereof
MY185802A (en) Antibody formulation
PH12018501153A1 (en) Novel anti-claudin antibodies and methods of use
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
UY37456A (es) Inmunoglobulinas y sus usos
MX2022002106A (es) Formulaciones de vacuna de vial unico.
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
EA201592203A1 (ru) Способы лечения таупатии
BR112018010102A2 (pt) conjugados farmacêuticos de anticorpos sítio-específicos para her2
MX2018015268A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2019004690A (es) Constructos de anticuerpos.
DK3661968T3 (da) Nanopartikelplatform til antistof- og vaccineindgivelse